Business Description
Vivoryon Therapeutics N.V. is a German clinical-stage company developing small molecule drugs to treat Alzheimer's disease by targeting a harmful protein fragment known as pyroglutamate-Abeta. Its lead drug, PQ912, has already completed mid-stage clinical trials, and the company is also working on an antibody therapy aimed at the same disease target. Vivoryon works alongside several partners, including Nordic Bioscience, the Fraunhofer Institute, and Simcere Pharmaceutical Group, to advance and bring these treatments to patients. Founded in 1997 and headquartered in Halle, Germany, the company is focused on turning its research into viable options for those affected by Alzheimer's.
